Quantum-Si (NASDAQ:QSI) Releases Quarterly Earnings Results, Beats Expectations By $0.06 EPS

Quantum-Si (NASDAQ:QSI) released its quarterly earnings data on Tuesday. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.06, FiscalAI reports. Quantum-Si had a negative net margin of 3,677.97% and a negative return on equity of 47.90%. The company had revenue of $0.45 million during the quarter, compared to analyst estimates of $0.76 million.

Here are the key takeaways from Quantum-Si’s conference call:

• Quantum-Si calls 2026 a deliberate “transition year” with total revenue guidance of approximately $1.0M, expecting very modest capital sales and revenue driven primarily by consumable utilization as the company prioritizes market preparation for Proteus.
• The company announced a list price of $425,000 for Proteus, says prototypes outperform the current system across key metrics, and expects instrument development to be on track for an end‑of‑2026 commercial launch with detection of 18 amino acids at launch and demonstration of all 20 during 2026.
• A capital‑efficient placement program has added 17 new customers, increased consumable run rates (management expects >25% consumable kit volume growth baked into 2026 guidance), and helped build a publication pipeline—early 2026 releases include clinical proteomics and rapid pathogen detection use cases.
• The balance sheet remains strong with $215.8M in cash and marketable securities at year‑end; management guided adjusted operating expenses ≤ $98M and total cash usage ≤ $93M for 2026, projecting runway into Q2 2028 to fund Proteus completion and commercial readiness.
• Recent financials show Q4 revenue of $451K and FY2025 revenue of $2.4M (Q4 gross margin 27%, FY gross margin 47%), with margins and Q4 results impacted by a higher consumable mix and inventory adjustments; management highlights year‑over‑year reductions in adjusted OpEx driven by cost discipline.

Quantum-Si Stock Up 1.6%

Shares of Quantum-Si stock opened at $0.95 on Wednesday. The business has a 50 day moving average of $1.12 and a 200 day moving average of $1.38. Quantum-Si has a 52 week low of $0.89 and a 52 week high of $3.10. The company has a market cap of $204.28 million, a PE ratio of -1.41 and a beta of 3.00.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the stock. Canaccord Genuity Group cut their price objective on shares of Quantum-Si from $2.00 to $1.50 and set a “hold” rating on the stock in a research report on Monday, December 22nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Quantum-Si in a report on Monday, December 29th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $3.55.

Insiders Place Their Bets

In other Quantum-Si news, insider John S. Vieceli sold 21,927 shares of the company’s stock in a transaction on Monday, December 22nd. The shares were sold at an average price of $1.28, for a total value of $28,066.56. Following the completion of the transaction, the insider directly owned 800,973 shares in the company, valued at approximately $1,025,245.44. This represents a 2.66% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Jeffrey Alan Hawkins sold 23,707 shares of Quantum-Si stock in a transaction dated Monday, December 22nd. The shares were sold at an average price of $1.28, for a total transaction of $30,344.96. Following the sale, the chief executive officer directly owned 2,578,018 shares in the company, valued at $3,299,863.04. The trade was a 0.91% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 54,261 shares of company stock worth $69,454. Insiders own 22.95% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Virtu Financial LLC purchased a new position in shares of Quantum-Si in the 4th quarter valued at approximately $262,000. Invesco Ltd. raised its holdings in Quantum-Si by 36.2% in the fourth quarter. Invesco Ltd. now owns 402,821 shares of the company’s stock worth $443,000 after purchasing an additional 107,093 shares in the last quarter. XTX Topco Ltd lifted its position in Quantum-Si by 206.9% during the fourth quarter. XTX Topco Ltd now owns 461,982 shares of the company’s stock valued at $508,000 after buying an additional 311,450 shares during the period. Quadrature Capital Ltd bought a new stake in shares of Quantum-Si during the 4th quarter valued at $305,000. Finally, Barclays PLC boosted its holdings in shares of Quantum-Si by 21.8% during the 4th quarter. Barclays PLC now owns 269,415 shares of the company’s stock valued at $296,000 after buying an additional 48,205 shares in the last quarter. Institutional investors own 39.90% of the company’s stock.

About Quantum-Si

Quantum-Si Inc is a life sciences instrumentation company headquartered in Guilford, Connecticut, developing next-generation proteomics solutions based on semiconductor sequencing technology. The company’s core offering centers on a proprietary single-molecule protein sequencing platform that uses a silicon-based sensor chip to convert protein data into digital signals. This approach is designed to deliver high sensitivity, single-amino-acid resolution and deep proteome coverage while potentially reducing cost and complexity compared to traditional mass spectrometry methods.

Quantum-Si’s product roadmap includes the development and commercialization of an integrated system comprising instruments, consumable reagents and proprietary data analysis software.